SG11201700971XA - Methods to enhance nerve regeneration utilizing neural stem cells and il12p40 - Google Patents

Methods to enhance nerve regeneration utilizing neural stem cells and il12p40

Info

Publication number
SG11201700971XA
SG11201700971XA SG11201700971XA SG11201700971XA SG11201700971XA SG 11201700971X A SG11201700971X A SG 11201700971XA SG 11201700971X A SG11201700971X A SG 11201700971XA SG 11201700971X A SG11201700971X A SG 11201700971XA SG 11201700971X A SG11201700971X A SG 11201700971XA
Authority
SG
Singapore
Prior art keywords
il12p40
methods
stem cells
neural stem
nerve regeneration
Prior art date
Application number
SG11201700971XA
Other languages
English (en)
Inventor
Ing-Ming Chiu
Ya-Hui Chi
Don-Ching Lee
Original Assignee
Nat Health Research Institutes
Chong Pele Choi Sing
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nat Health Research Institutes, Chong Pele Choi Sing filed Critical Nat Health Research Institutes
Publication of SG11201700971XA publication Critical patent/SG11201700971XA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/208—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/50—Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Materials For Medical Uses (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
SG11201700971XA 2014-08-15 2015-08-14 Methods to enhance nerve regeneration utilizing neural stem cells and il12p40 SG11201700971XA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462037612P 2014-08-15 2014-08-15
PCT/CA2015/050775 WO2016023130A1 (en) 2014-08-15 2015-08-14 Methods to enhance nerve regeneration utilizing neural stem cells and il12p40

Publications (1)

Publication Number Publication Date
SG11201700971XA true SG11201700971XA (en) 2017-03-30

Family

ID=55303739

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201700971XA SG11201700971XA (en) 2014-08-15 2015-08-14 Methods to enhance nerve regeneration utilizing neural stem cells and il12p40

Country Status (11)

Country Link
US (2) US10391149B2 (ja)
EP (1) EP3180019B1 (ja)
JP (1) JP6339737B2 (ja)
KR (1) KR101897422B1 (ja)
CN (1) CN107148278B (ja)
AU (1) AU2015303798B2 (ja)
CA (1) CA2958398C (ja)
HK (1) HK1243648A1 (ja)
SG (1) SG11201700971XA (ja)
TW (1) TWI694828B (ja)
WO (1) WO2016023130A1 (ja)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114126608A (zh) 2019-07-08 2022-03-01 得克萨斯州大学系统董事会 使用免疫调节剂来改善神经再生
CN110938598B (zh) * 2019-12-31 2020-10-02 重庆市铂而斐细胞生物技术有限公司 一种许旺细胞的培养方法及其应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA02001719A (es) * 1999-08-18 2003-09-25 Childrens Medical Center METODOS, COMPOSICIONES Y EQUIPOS PARA PROMOVER LA RECUPERACION DEL DAnO AL SISTEMA NERVIOSO CENTRAL.
JP2002078792A (ja) * 2000-09-07 2002-03-19 Kuraray Co Ltd 神経再生用材料
DE60231263D1 (de) * 2001-03-12 2009-04-02 Inst Of Gene And Brain Science Granulocyte-macrophage colony-stimulating factor (GM-CSF) als Heilmittel für Nervenschäden
CN101306194A (zh) * 2008-06-20 2008-11-19 奔驰生物科技（云南）有限公司 一种神经损伤治疗药物及其制备方法

Also Published As

Publication number Publication date
EP3180019A4 (en) 2018-05-09
TW201613623A (en) 2016-04-16
KR101897422B1 (ko) 2018-09-10
US20170224776A1 (en) 2017-08-10
HK1243648A1 (zh) 2018-07-20
AU2015303798B2 (en) 2020-03-12
US10391149B2 (en) 2019-08-27
EP3180019B1 (en) 2019-12-25
CA2958398A1 (en) 2016-02-18
CA2958398C (en) 2019-05-14
TWI694828B (zh) 2020-06-01
AU2015303798A1 (en) 2017-03-02
KR20170065504A (ko) 2017-06-13
JP6339737B2 (ja) 2018-06-06
CN107148278B (zh) 2021-06-29
WO2016023130A1 (en) 2016-02-18
EP3180019A1 (en) 2017-06-21
JP2017529329A (ja) 2017-10-05
US20190351022A1 (en) 2019-11-21
CN107148278A (zh) 2017-09-08

Similar Documents

Publication Publication Date Title
IL251429A0 (en) A method for modulating immune cell activity caused by a chimeric antigen receptor
SG11201606934SA (en) Improved reprogramming methods and cell culture platforms
SG11201701356WA (en) Solar cell and method for producing thereof
HK1245132A1 (zh) 改善細胞治療的方法
IL285258A (en) Retinal ganglion cells and their progenitor cells
ZA201607022B (en) Encoded cells and cell arrays
HK1249662A1 (zh) 電池電極和方法
ZA201703343B (en) Control systems and methods suitable for use with power production systems and methods
EP3037812C0 (en) ENZYME ELECTRODE
SG11201609998SA (en) Solar cell and method for producing solar cell
IL254156A0 (en) Methods for producing neural stem cells and their use
HUE057737T2 (hu) Õssejtstimuláló készítmények és eljárások
EP3137082A4 (en) Methods to treat, prevent, and improve skin conditions
SG11201701418RA (en) Solar cell and manufacturing method of solar cell
IL247890A0 (en) Methods related to stem cells
PL3128838T3 (pl) Stymulatory roślin, ich zastosowanie i sposób stymulacji roślin
HK1243648A1 (zh) 利用神經幹細胞與il12p40增强神經再生的方法
SG11201703600YA (en) Method of distinguishing mesenchymal stem cells
EP3139996A4 (en) Neural stimulator
SG10201403640XA (en) Stem cells
GB201420088D0 (en) Battery modules and methods for their manufacture
SG10201800796XA (en) Method of distinguishing mesenchymal stem cells
IL236273A0 (en) Cells and battery organizers